home / stock / pyxs / pyxs quote
Last: | $2.94 |
---|---|
Change Percent: | 0.63% |
Open: | $3.18 |
Close: | $2.94 |
High: | $3.18 |
Low: | $2.92 |
Volume: | 892,879 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.94 | $3.18 | $2.94 | $3.18 | $2.92 | 892,879 | 07-02-2024 |
$3.2 | $3.28 | $3.2 | $3.29 | $3.045 | 766,942 | 07-01-2024 |
$3.31 | $3.22 | $3.31 | $3.5 | $3.13 | 7,130,601 | 06-28-2024 |
$3.21 | $3.15 | $3.21 | $3.36 | $3.11 | 485,209 | 06-27-2024 |
$3.21 | $3.04 | $3.21 | $3.21 | $2.95 | 668,940 | 06-26-2024 |
$3.06 | $3.19 | $3.06 | $3.29 | $3.04 | 705,795 | 06-25-2024 |
$3.19 | $3.36 | $3.19 | $3.395 | $3.15 | 275,265 | 06-24-2024 |
$3.37 | $3.4 | $3.37 | $3.43 | $3.3 | 1,209,055 | 06-21-2024 |
$3.38 | $3.41 | $3.38 | $3.54 | $3.345 | 390,672 | 06-20-2024 |
$3.42 | $3.7 | $3.42 | $3.7 | $3.4 | 465,868 | 06-19-2024 |
$3.42 | $3.7 | $3.42 | $3.7 | $3.4 | 465,868 | 06-18-2024 |
$3.66 | $3.76 | $3.66 | $3.905 | $3.66 | 439,334 | 06-17-2024 |
$3.79 | $3.9 | $3.79 | $3.98 | $3.76 | 174,757 | 06-14-2024 |
$3.95 | $3.86 | $3.95 | $4 | $3.78 | 226,970 | 06-13-2024 |
$3.85 | $3.96 | $3.85 | $4.1 | $3.8275 | 351,600 | 06-12-2024 |
$3.925 | $3.9 | $3.925 | $4.04 | $3.8701 | 271,072 | 06-11-2024 |
$3.97 | $3.88 | $3.97 | $4.05 | $3.73 | 750,986 | 06-10-2024 |
$3.8 | $3.48 | $3.8 | $3.88 | $3.48 | 924,383 | 06-07-2024 |
$3.54 | $3.5 | $3.54 | $3.6099 | $3.44 | 278,210 | 06-06-2024 |
$3.62 | $3.67 | $3.62 | $3.6951 | $3.585 | 317,813 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway i...